CA3183852A1 - Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib - Google Patents

Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib

Info

Publication number
CA3183852A1
CA3183852A1 CA3183852A CA3183852A CA3183852A1 CA 3183852 A1 CA3183852 A1 CA 3183852A1 CA 3183852 A CA3183852 A CA 3183852A CA 3183852 A CA3183852 A CA 3183852A CA 3183852 A1 CA3183852 A1 CA 3183852A1
Authority
CA
Canada
Prior art keywords
rcc
cancer
lenvatinib
hif
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3183852A
Other languages
English (en)
French (fr)
Inventor
Rodolfo Fleury Perini
Elaine M. Pinheiro
Jaqueline WILLEMANN ROGERIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Merck Sharp and Dohme LLC
Original Assignee
Eisai R&D Management Co Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd, Merck Sharp and Dohme LLC filed Critical Eisai R&D Management Co Ltd
Publication of CA3183852A1 publication Critical patent/CA3183852A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3183852A 2020-06-22 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib Pending CA3183852A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063042307P 2020-06-22 2020-06-22
US63/042,307 2020-06-22
US202163146915P 2021-02-08 2021-02-08
US63/146,915 2021-02-08
PCT/US2021/038172 WO2021262563A1 (en) 2020-06-22 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib

Publications (1)

Publication Number Publication Date
CA3183852A1 true CA3183852A1 (en) 2021-12-30

Family

ID=79281740

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3183852A Pending CA3183852A1 (en) 2020-06-22 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib

Country Status (10)

Country Link
US (1) US20230210838A1 (https=)
EP (1) EP4168008B1 (https=)
JP (1) JP7750884B2 (https=)
KR (1) KR20230026493A (https=)
CN (1) CN115803629A (https=)
AU (1) AU2021296151A1 (https=)
BR (1) BR112022026094A2 (https=)
CA (1) CA3183852A1 (https=)
MX (2) MX2022016406A (https=)
WO (1) WO2021262563A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
CN119731864A (zh) 2023-02-28 2025-03-28 株式会社Lg新能源 电化学装置用分隔件和包括其的电化学装置
AU2024248799A1 (en) * 2023-03-31 2025-10-23 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168510A1 (en) * 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
WO2020081695A1 (en) * 2018-10-17 2020-04-23 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors

Also Published As

Publication number Publication date
EP4168008A1 (en) 2023-04-26
JP7750884B2 (ja) 2025-10-07
JP2023531675A (ja) 2023-07-25
MX2025014865A (es) 2026-01-07
US20230210838A1 (en) 2023-07-06
EP4168008B1 (en) 2026-03-18
MX2022016406A (es) 2023-01-30
CN115803629A (zh) 2023-03-14
EP4168008A4 (en) 2024-08-07
WO2021262563A1 (en) 2021-12-30
AU2021296151A1 (en) 2023-02-02
BR112022026094A2 (pt) 2023-01-17
KR20230026493A (ko) 2023-02-24

Similar Documents

Publication Publication Date Title
EP4168008B1 (en) A combination of belzutifan and lenvatinib for use in treating cancer
US20230181565A1 (en) Crenolanib combination therapy
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
Scaringi et al. Combining molecular targeted agents with radiation therapy for malignant gliomas
JP2025509510A (ja) 乳がんのための併用療法
Koukourakis et al. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer
US20260053791A1 (en) Use of tivozanib to treat subjects with refractory cancer
TWI771344B (zh) 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途
RU2858600C2 (ru) Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли
JP7308145B2 (ja) 固形腫瘍を治療するための医薬組成物
JP7504106B2 (ja) がんの処置のための組合せ物
HK40087480A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
US20210113692A1 (en) Dosing regimen
Yu et al. 1190TiP Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Shah et al. Evaluating alternative ramucirumab doses as a single agent or with paclitaxel in second-line treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: results from two randomized, open-label, phase II studies. Cancers (Basel). 2022; 14: 1168
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
WO2024231875A1 (en) Hpk1 inhibitor for use in the treatment of cancer
Wagner Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs
JP2024531653A (ja) 固形腫瘍の処置のための経口投与パクリタキセル、Ｐ－ｇｐ阻害剤、およびチェックポイント阻害剤の治療的組み合わせ
Theodore et al. Topoisomerase Therapy in
JP2024540399A (ja) Ｍｅｔ受容体チロシンキナーゼ阻害剤を含む薬物の組み合わせ及びその使用
Wu et al. Molecularly targeted therapy for metastatic colon cancer: Proven treatments and promising new agents
de Souza et al. Molecularly Targeted Agents in Recurrent, Metastatic Squamous Cell Carcinoma of the Head and Neck
Gerber et al. Docetaxel Plus Bavituximab in Previously Treated, Advanced Nonsquamous Non–small-cell Lung Cancer
Kiyota 392 A phase IA, dose-escalating study of LBH589 administered intravenously in adult patients with advanced solid tumors

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250506

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250506

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250619

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250619

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250619

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250625

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250902

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250902

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250902

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250903

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401